TCRX triangle breakoutabout to retrace the recent highs as a bare minimum. floor strengthen by the dilution price fo 2
−1.89USD
−89.22 MUSD
21.05 MUSD
36.46 M
About TScan Therapeutics, Inc.
Sector
Industry
CEO
Gavin MacBeath
Website
Headquarters
Waltham
Employees (FY)
154
Founded
2018
FIGI
BBG00PH1N007
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
$TCRX is giving a GREAT IPO SHORT opportunity todayIPO intraday trading strategy idea
The share price is falling and gonna continue this trend today.
The demand for shares of the company still looks lower than the supply.
These and other conditions can cause a fall in the share price today.
So I opened a short position from $10,88;
stop-loss — $
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TCRX is 7.38 USD — it has increased by 1.65% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TScan Therapeutics, Inc. stocks are traded under the ticker TCRX.
TScan Therapeutics, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
TCRX stock is 5.63% volatile and has beta coefficient of 0.62. Check out the list of the most volatile stocks — is TScan Therapeutics, Inc. there?
TCRX earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.45 USD resulting in a 46.97% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about TScan Therapeutics, Inc. earnings.
TScan Therapeutics, Inc. revenue for the last quarter amounts to 3.89 M USD despite the estimated figure of 4.45 M USD. In the next quarter revenue is expected to reach 3.45 M USD.
Yes, you can track TScan Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TCRX stock has risen by 1.51% compared to the previous week, the month change is a 7.87% fall, over the last year TScan Therapeutics, Inc. has showed a 190.55% increase.
TCRX net income for the last quarter is −19.61 M USD, while the quarter before that showed −23.00 M USD of net income which accounts for 14.71% change. Track more TScan Therapeutics, Inc. financial stats to get the full picture.
Today TScan Therapeutics, Inc. has the market capitalization of 334.69 M, it has increased by 5.52% over the last week.
No, TCRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TCRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TScan Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 154.00 employees. See our rating of the largest employees — is TScan Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TScan Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TScan Therapeutics, Inc. stock shows the buy signal. See more of TScan Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on TScan Therapeutics, Inc. future price: according to them, TCRX price has a max estimate of 15.00 USD and a min estimate of 9.00 USD. Read a more detailed TScan Therapeutics, Inc. forecast: see what analysts think of TScan Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TScan Therapeutics, Inc. EBITDA is −88.10 M USD, and current EBITDA margin is −418.53%. See more stats in TScan Therapeutics, Inc. financial statements.